Navigation Links
ThromboGenics N.V. - Business Update
Date:5/13/2008

s trial will be presented by the lead investigator, Prof. Peter Stalmans, at the Euretina Conference on May 23, in Vienna. The third and fourth cohorts from this trial will be presented at major ophthalmic conferences in the second half of 2008.

- Results are expected from the Phase II MITI IV trial in mid 2008.

This Phase II trial is evaluating the safety and preliminary efficacy of microplasmin when administered intravenously to acute stroke patients. Once these data from the study have been reviewed, a decision will be made on the future development plans for microplasmin in the treatment of acute stroke.

It is ThromboGenics' current intention that it will only move forward with the development of microplasmin for the treatment of stroke in conjunction with a partner. This intention is based on both the risks and cost associated with the development of new stroke therapies and the Company's desire to invest in its other attractive pipeline product candidates, such as microplasmin in the treatment of back of the eye diseases and TB-403.

TB-403

- Results from the initial Phase I trial of this novel anti-cancer agent in healthy volunteers are expected in the third quarter of 2008.

Following the successful completion of this initial Phase I study, ThromboGenics expects to begin a Phase Ib trial with TB-403 in end stage cancer patients in mid 2008. This study, which will recruit approximately 24 patients, is designed to provide both safety data on TB-403 when used in cancer patients and some early efficacy data on the product.

TB-402

- Top line results of the interaction studies to be announced by mid-2008.

TB-402 is being developed as an anti-coagulant for the prevention of deep vein thrombosis (DVT) after orthopaedic surgery and prevention of venous emboli in patients with atrial fibrillation. It is a novel human antibody that partially blocks Factor VIII, an essential blood clotting factor. The implicat
'/>"/>

SOURCE ThromboGenics NV
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007
2. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
3. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
4. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
5. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
6. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
7. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
8. ThromboGenics Announces 2007 Full Year Results
9. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
10. Boston Scientific to Explore Sale of Cardiac Surgery and Vascular Surgery Businesses
11. DuPont Leaders Brief Investors on Agriculture Businesses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)...  RegeneRx Biopharmaceuticals, Inc. (OTCBB: RGRX) ("the Company" or ... International Symposium on Thymosins in Health and Disease in ... "When thymosin beta 4 (TB4) linked with rhodamine (a ... in a rodent model of stroke, it was visualized ... (the functional tissue of the brain).   The leakage of ...
(Date:10/25/2014)... 2014 Research and Markets has ... Product , Research Area & by End User - ... In this report, the global epigenetics ... areas, and end users. The product segments of the ... & consumables, kits, and reagents. The subsegments of the ...
(Date:10/22/2014)... New test innovations will be the source ... test industry, especially as companies struggle with reimbursement challenges, ... than 25 testing innovations in important disease areas in ... products. Kalorama details the new approaches its biennial survey of ... Vitro Diagnostic Tests , 9th Edition . ...
(Date:10/22/2014)... , Oct. 22, 2014  Actavis plc (NYSE: ... company, and Rhythm, a biopharmaceutical company, today announced that ... Rhythm,s wholly owned subsidiary, Rhythm Health, Inc., which is ... treatment of diabetic gastroparesis and other GI functional disorders. ... 2 trial of relamorelin for the treatment of diabetic ...
Breaking Biology Technology:Researchers Report Thymosin Beta 4 Crosses Blood-Brain Barrier In Animal Stroke Model 2Global Epigenetics (VLA, WBA, NBA, RTA, Rotary-Wing Aircraft) Market - Forecast to 2019 2Global Epigenetics (VLA, WBA, NBA, RTA, Rotary-Wing Aircraft) Market - Forecast to 2019 3Report: Radical New IVD Test Approaches Key To Growth 2Report: Radical New IVD Test Approaches Key To Growth 3Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 2Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 3Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 4Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 5
... of senior living community, LISLE, Ill., ... leading,faith-based continuing care retirement community located in ... newly redesigned web site,( http://www.VillaStBen.org ). The ... residents, and provides in-depth information and support ...
... GenVault Corporation today,announces Paul J. Mirabella, Chairman and ... Board of Directors. Mr. Mirabella has more than ... Healthcare where he held,leadership roles in technology, marketing ... in diagnostics and the healthcare,market, he will help ...
... Restore Shareholder Value Following NEBIDO(R) ... ... IDEV ) today announced that Glenn L. Cooper,MD, its chairman and chief ... challenges,it faces as a result of the recent delay in the approval ...
Cached Biology Technology:Villa St. Benedict Announces New Web Site 2Paul J. Mirabella, President and CEO of Naviscan PET Systems Inc., Joins GenVault's Board of Directors 2Indevus Announces Management Changes 2Indevus Announces Management Changes 3Indevus Announces Management Changes 4
(Date:10/25/2014)... Oct. 23, 2014 Research and Markets ... in Europe 2014-2018" report to their offering. ... assess individuals on the basis of their physical or ... both physiological traits such as fingerprints, face recognition, DNA, ... traits such as keystroke patterns and speech pattern/voice recognition. ...
(Date:10/22/2014)... identity analyst firm Acuity Market Intelligence forecasts that in ... have a chip-based National eID card, including near-complete regional ... Asia , with its vast population, is expected ... of all National eID cards issued between 2014 and ... National eID Industry Report: 2014 Edition" — projects ...
(Date:10/18/2014)... Berlin, 19th October 2014 Psychological stress and stress-related ... for aging-related diseases, but the molecular mechanisms ... mechanisms may contribute to the development of ... treatments for these devastating diseases. This work ... Neuropsychopharmacology congress in Berlin., Now an international ...
Breaking Biology News(10 mins):Biometrics Market in Europe 2014-2018: Key Vendors are 3M Cogent, Cognitec, NEC and Safran 2Biometrics Market in Europe 2014-2018: Key Vendors are 3M Cogent, Cognitec, NEC and Safran 3Half the World's Population Will Have Chip-Based National Electronic Identity (eID) Cards by 2018 2Researchers find why depression and aging linked to increased disease risk 2
... threatened forest frogs to disappear, paving the way for ... have revealed. The study, carried out by the ... to palm oil plantations are causing threatened forest dwelling ... habitat that is important for the conservation of threatened ...
... the most commonly cultivated cacao plant in the world ... this week. Researchers have utilised high quality DNA sequences to ... markers that can lead to higher yielding cocoa plants that still ... the cacao tree ( Theobroma cacao L. ...
... the University of Georgia, Athens, have identified a strong ... pathogens on poultry farms, and later downstream at the ... published ahead of print in the journal Applied ... reducing foodborne pathogen loads on broiler chicken farms would ...
Cached Biology News:Threatened frogs palmed off as forests disappear 2Genome hints at markers for higher-producing, better-tasting chocolate 2Investigators link poultry contamination on farm and at processing plant 2
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
CD69/CD3 50 tests...
Rat polyclonal to Vitamin B3 ( Abpromise for all tested applications). Antigen: Chemical / Small Molecule, Vitamin B3 conjugated to BSA....
Phospho-CD18 (Ser756/Thr758/759) Antibody Shipping Temperature: HOT Storage Temperature: -20C...
Biology Products: